Lymphocyte adoptive immunotherapy

Isolated human lymphocytes are used to investigate the role of these cells in the pathogenesis of various diseases and in the autologous adoptive immunotherapy for patients with malignant disease or viral infections [39,40], Lymphocytes may be used also as biomarkers of target-organ susceptibility or as a marker of chemical effects and in the prediction of individual drug sensitivity alternatively to human liver biopsies [41, 42]. 

The obtained results demonstrated that a PEEK-WC-H F membrane bioreactor is able to support the proliferation and functions of human peripheral lymphocytes isolated from the buffy coat of healthy individuals. Therefore, the lymphocyte HF membrane bioreactor can be used as a valuable tool to maintain viable and functional lymphocytes and as an in-vitro model for pharmacological and adoptive immunotherapy. 

Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 1986 233 1318-21. 

IL-12 may also be potentially useful for adoptive immunotherapy, especially in immunosuppressed patients (caused by cancer or HIV infection) with decreased NK function and T-cell cytotoxicity. Under appropriate conditions, IL-12 has therapeutic efficacy for promoting defense against a variety of pathogens and for use as a vaccine adjuvant to enhance beneficial Thl over detrimental Th2 lymphocyte responses and provides new tools for the development of treatment and adjuvant strategies to potentiate beneficial or inhibit detrimental endogenous immune responses. ... 

Baron F, Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 2000 40 468-476. 

Yamaguchi, Y, A. Ohshita, Y. Kawabuchi, K. Ohta, K. Shimizu, K. Minami, J. Hihara, E. Miyahara, and T. Toge (2003) Adoptive immunotherapy of cancer using activated autologous lymphocytes - current status and new strategies. Hum Cell 16 183-189. 

Chang AE, Yoshizawa H, Sakai K, Cameron Ml, Sondak VK, Shu S. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 1993 53 1043-1050. 

Jicha DL, Mule JJ, Rosenberg SA. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. JExpMed 1991 174 1511-1515. 

In almost 40% of HL patients, H/RSCs express EBV-associated antigens. EBV-specihc cytotoxic T lymphocytes expressing the anti-CD30 artificial chimeric T-cell receptor have been employed for immunotherapy of HL. Adoptive transfer of EBV-specific cytotoxic T lymphocytes (EBV-CTLs) have shown that these cells persist in patients with HL to produce complete tumor responses.Treatment failure occurs if a subpopulation of malignant cells lacks or loses expression of EBV antigens. To overcome this limitation, investigators have prepared EBV-CTLs that retained antitumor... 

Finally, mention should be made of a promising new class of cancer immunotherapy undergoing early-stage testing. In this therapy, called adoptive cell transfer (ACT), tumor-reactive lymphocytes are harvested from a patient with melanoma, activated and expanded ex vivo, and then infused back into the patient. The result, in many patients, is the production of lymphocytes with increased tumor-fighting capacity. Research is ongoing to optimize clinical results from this type of treatment. 

Metastatic melanoma remained an essentially incurable disease with prolongation of life only in response to chemo-immunotherapy. Non-curative partial responses were induced by dacarbazine (5 %), cisplatin, IFNa, IL-2 disease terminated in relapses with deaths delayed. Major clinical responses (partial remissions, durable complete remissions) are achieved with intravenous immune adoptive lymphocyte (immune T cell NKT/LAK cells and IL-2) therapy curative outcome is rare but possible. ... 

---